Skip Nav Destination
Issues
1 October 2023
-
Cover Image
Cover Image
Proposed mechanism of action of the MDA-9/Syntenin-1/SDCBP pharmacological inhibitor IVMT-Rx-3. Through the disruption of the interactions between MDA-9/Syntenin and cSrc, IVMT-Rx-3 deactivates NF-κB suppressing invasion and angiogenesis associated genes and blocking tumor cell migration. Additionally, IVMT-Rx-3 inhibits the expression of NF-κB dependent inflammatory cytokine expression, boosting anti-tumor immunity and blocking the proliferation of melanoma cells in the metastatic niche. Read the full article on page 1115. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1535-7163
EISSN 1538-8514
Highlights
First Disclosures
Dual Targeting of the PDZ1 and PDZ2 Domains of MDA-9/Syntenin Inhibits Melanoma Metastasis
Anjan K. Pradhan; Jinkal Modi; Santanu Maji; Amit Kumar; Praveen Bhoopathi; Padmanabhan Mannangatti; Chunqing Guo; Daniel K. Afosah; Mark C. Mochel; Nitai D. Mukhopadhyay; John M. Kirkwood; Xiang-Yang Wang; Umesh R. Desai; Devanand Sarkar; Luni Emdad; Swadesh K. Das; Paul B. Fisher
Review
Small Molecule Therapeutics
First-in-human Study of AZD5153, A Small-molecule Inhibitor of Bromodomain Protein 4, in Patients with Relapsed/Refractory Malignant Solid Tumors and Lymphoma
Erika P. Hamilton; Judy S. Wang; Amit M. Oza; Manish R. Patel; Susanna V. Ulahannan; Todd Bauer; Janet L. Karlix; Jorge Zeron-Medina; Giulia Fabbri; Paola Marco-Casanova; Ganesh Moorthy; Maureen M. Hattersley; Gillian M. Littlewood; Patrick Mitchell; Jamal Saeh; Gayle P. Pouliot; Kathleen N. Moore
A Multivalent Peptoid Conjugate Modulates Androgen Receptor Transcriptional Activity to Inhibit Therapy-resistant Prostate Cancer
Justine Habault; Jeffrey A. Schneider; Susan Ha; Rachel Ruoff; Luiza D. Pereira; Joseph Puccini; Michela Ranieri; Ruveyda Ayasun; Jiehui Deng; Amanda C. Kasper; Dafna Bar-Sagi; Kwok-Kin Wong; Amina Zoubeidi; Frank Claessens; David R. Wise; Susan K. Logan; Kent Kirshenbaum; Michael J. Garabedian
Conditional Dependency of LP-184 on Prostaglandin Reductase 1 is Synthetic Lethal in Pancreatic Cancers with DNA Damage Repair Deficiencies
Diana Restifo; Joseph R. McDermott; Dusica Cvetkovic; Troy Dos Santos; Charline Ogier; Aizhan Surumbayeva; Elizabeth A. Handorf; Caleb Schimke; Charlie Ma; Kathy Q. Cai; Anthony J. Olszanski; Umesh Kathad; Kishor Bhatia; Panna Sharma; Aditya Kulkarni; Igor Astsaturov
Large Molecule Therapeutics
Safety and Tolerability of a Novel Anti-HER2 Antibody–Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study
Funda Meric-Bernstam; Emiliano Calvo; Keun Seok Lee; Victor Moreno; Yeon Hee Park; Sun Young Rha; Pavani Chalasani; Wei Zhong; Li Zhou; Steven Pirie-Shepherd; Abraham C.F. Leung; Giuseppe Curigliano
Targeting Solid Cancers with a Cancer-Specific Monoclonal Antibody to Surface Expressed Aberrantly O-glycosylated Proteins
Mikkel K.M. Aasted; Aaron C. Groen; John T. Keane; Sally Dabelsteen; Edwin Tan; Julia Schnabel; Fang Liu; Hyeon-Gyu S. Lewis; Constantine Theodoropulos; Avery D. Posey, Jr; Hans H. Wandall
Targeting Drug Resistance
Advertisement
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds
